Aligos Therapeutics (FRA:5WK) 3-Year EBITDA Growth Rate : 48.10% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aligos Therapeutics 3-Year EBITDA Growth Rate?

Aligos Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.13.

During the past 3 years, the average EBITDA Per Share Growth Rate was 48.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aligos Therapeutics was 48.10% per year. The lowest was 2.30% per year. And the median was 25.20% per year.

Competitive Comparison of Aligos Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Aligos Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aligos Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's 3-Year EBITDA Growth Rate falls into.

Aligos Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aligos Therapeutics (FRA:5WK) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Aligos Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aligos Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aligos Therapeutics (FRA:5WK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aligos Therapeutics Inc (FRA:5WK) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ALGS:USA

Address

One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080

Website

https://www.aligos.com

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Aligos Therapeutics (FRA:5WK) Headlines

No Headlines